A Critical Appraisal of Non-Invasive Technologies in NASH
Informing the Future of NASH Diagnosis and Assessment
Noninvasive tests accurately identify advanced fibrosis due to NASH: baseline data from the STELLAR trials.
Anstee QM, Lawitz EJ, Alkhouri N, et al. Hepatology. 2019;70(5):1521-1530.
Management of nonalcoholic fatty liver disease in patients with type 2 diabetes: a call to action.
Bril F, Cusi K. Diabetes Care. 2017;40(3):419-430.
Increased risk of mortality by fibrosis stage in nonalcoholic fatty liver disease: systematic review and meta-analysis.
Dulai PS, Singh S, Patel J, et al. Hepatology. 2017;65(5):1557-1565.
Accuracy of FibroScan controlled attenuation parameter and liver stiffness measurement in assessing steatosis and fibrosis in patients with nonalcoholic fatty liver disease.
Eddowes PJ, Sasso M, Allison M, et al. Gastroenterology. 2019;156(6):1717-1730.
Advanced liver fibrosis is common in patients with type 2 diabetes followed in the outpatient setting: the need for systematic screening.
Lomonaco R, Godinez Leiva E, Bril F, et al. Diabetes Care. 2021;44(2):399-406.
Screening for nonalcoholic fatty liver disease in persons with type 2 diabetes in the United States Is cost-effective: a comprehensive cost-utility analysis.
Noureddin M, Jones C, Alkhouri N, et al. Gastroenterology. 2020;159(5):1985-1987.e1984.
Vibration-controlled transient elastography to assess fibrosis and steatosis in patients with nonalcoholic fatty liver disease.
Siddiqui MS, Vuppalanchi R, Van Natta ML, et al. Clin Gastroenterol Hepatol. 2019;17(1):156-163.e152.
Prospective evaluation of a primary care referral pathway for patients with non-alcoholic fatty liver disease.
Srivastava A, Gailer R, Tanwar S, et al. J Hepatol. 2019;71(2):371-378.
Update on NAFLD genetics: from new variants to the clinic.
Trépo E, Valenti L. J Hepatol. 2020;72(6):1196-1209.
The global epidemiology of NAFLD and NASH in patients with type 2 diabetes: a systematic review and meta-analysis.
Younossi ZM, Golabi P, de Avila L, et al. J Hepatol. 2019;71(4):793-801.
Performance of the enhanced liver fibrosis test to estimate advanced fibrosis among patients with nonalcoholic fatty liver disease.
Younossi ZM, Felix S, Jeffers T, et al. JAMA Netw Open. 2021;4(9):e2123923.
Role of noninvasive tests in clinical gastroenterology practices to identify patients with nonalcoholic steatohepatitis at high risk of adverse outcomes: expert panel recommendations.
Younossi ZM, Noureddin M, Bernstein D, et al. Am J Gastroenterol. 2021;116(2):254-262.
Clinical Practice Guidelines
American Association of Clinical Endocrinology clinical practice guideline for the diagnosis and management of nonalcoholic fatty liver disease in primary care and endocrinology clinical settings: co-sponsored by the American Association for the Study of Liver Diseases (AASLD).
Cusi K, Isaacs S, Barb D, et al. Endocr Pract. 2022;28(5):528-562.
